Abstract:In recent years, the U.S. Food and Drug Administration (FDA) has approved Chimeric Antigen Receptor (CAR)-T cell therapy as a novel approach to treating hematological diseases, including multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia. Using the patient's genetically altered T-cells, this novel strategy precisely targets antigens linked to cancer. Even with the encouraging outcomes of using bi-specific chimeric antigen receptors to stop tumor antigen evasion, difficulties still arise, especially when dealing with solid tumors. There are several challenges because of the intricate interactions among many elements in the tumor microenvironment, such as immunosuppression, hypoxia, decreased T-cell infiltration, elevated reactive oxygen species, and the erratic nature of tumor-associated antigens. This study examines current efforts to find reliable tumor-associated antigens in an attempt to address issues impeding the efficacy of CAR-T treatment. The fundamental objective is to create CAR-T cells that are economical while being adapted to the distinct characteristics of the tumor microenvironment. By means of a comprehensive analysis of the course of the therapy, the study explores its potential therapeutic uses for a range of tumor types, including solid and hematological malignancies. This work not only sheds light on the enormous obstacles to obtaining precision medicine in cancer treatment, but it also advances our knowledge of the promise that the specific therapy has. The presented results open the door for future developments in the field and provide a nuanced viewpoint on the revolutionary role that the treatment has played in the contemporary cancer scene.

Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies

Research Advances in Chimeric Antigen Receptor-Modified T-cell Therapy (Review)

Current state of CAR-T therapy for T-cell malignancies

CAR-T Cells for Cancer Immunotherapy—the Barriers Ahead and the Paths Through

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development

CAR-T Cell Therapy: Where Are We Now, and Where Are We Heading?

Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy

Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?

Recent advances in CAR-T cell engineering

[Chimeric antigen receptors in oncology: clinical applications and new developments]

Current progress in CAR-T cell therapy for tumor treatment

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review

Current Clinical Application of the CAR-T Cell Therapy